Amylyx Pharmaceuticals Inc (AMLX) Stock Analysis
Verdict: WATCH (do not buy)
Avexitide pipeline transition targets $570M revenue by 2029, but $123.5M annual burn limits cash runway to 22 months.
Investment score: 50/100
Analysis as of
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 40/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Amylyx Pharmaceuticals Inc opportunities and risks
What speaks for AMLX
- Long-term commercial ramp in avexitide for post-bariatric hypoglycemia
What speaks against AMLX
- Severe equity dilution risk within 22 months
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AMLX | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.5% |
| AMRX | 36.3x | 1.9x | 12.9x | 39.3% | 5.0% | 1.4% |
| LGND | 27.5x | 19.0x | 20.6x | 98.6% | 67.9% | 2.4% |
| DFTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.3% |
| EWTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.3% |
| MANE | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.8% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.8% |
Frequently asked questions about Amylyx Pharmaceuticals Inc (AMLX)
Is AMLX stock a good investment?
The TradeMates model rates Amylyx Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 50/100. Avexitide pipeline transition targets $570M revenue by 2029, but $123.5M annual burn limits cash runway to 22 months. This is algorithmic model output, not personal investment advice.
Is AMLX stock a buy?
The TradeMates model verdict for AMLX is WATCH (do not buy) with an investment score of 50/100. Treat this as a model signal to review, not a personal buy recommendation.